Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.325
Open
1.250
VWAP
1.26
Vol
165.61K
Mkt Cap
71.05M
Low
1.200
Amount
208.93K
EV/EBITDA(TTM)
--
Total Shares
22.91M
EV
29.97M
EV/OCF(TTM)
--
P/S(TTM)
8.21
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
1.39M
-16.56%
-0.333
-95.63%
1.56M
+28.6%
-0.313
-63.99%
1.93M
+86.36%
-0.225
-83.21%
Estimates Revision
The market is revising Downward the revenue expectations for Cibus, Inc. (CBUS) for FY2025, with the revenue forecasts being adjusted by -11.82% over the past three months. During the same period, the stock price has changed by -9.03%.
Revenue Estimates for FY2025
Revise Downward
-11.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-42.36%
In Past 3 Month
Stock Price
Go Down
-9.03%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast CBUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBUS is 20.00 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.310
Low
15.00
Averages
20.00
High
25.00
Current: 1.310
Low
15.00
Averages
20.00
High
25.00
Canaccord
Austin Moeller
Buy
downgrade
$18
2025-05-12
Reason
Canaccord
Austin Moeller
Price Target
$18
2025-05-12
downgrade
Buy
Reason
Canaccord analyst Austin Moeller lowered the firm's price target on Cibus to $17.50 from $18 and keeps a Buy rating on the shares. The firm noted Cibus is not yet generating meaningful commercial revenues at this point in the company's lifecycle. However, through contract research on behalf of customers relating to collaborative agreements for products and traits, the company has consistently generated some quarterly revenue in advance of major trait commercializations. Cibus' nearest-term revenue-generation opportunity continues is its sustainable ingredients biofragrance product pipeline.
HC Wainwright & Co.
Amit Dayal
Strong Buy
Reiterates
$25
2025-03-21
Reason
HC Wainwright & Co.
Amit Dayal
Price Target
$25
2025-03-21
Reiterates
Strong Buy
Reason
Canaccord Genuity
Austin Moeller
Strong Buy
Maintains
$20 → $18
2025-01-22
Reason
Canaccord Genuity
Austin Moeller
Price Target
$20 → $18
2025-01-22
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Amit Dayal
Strong Buy
Reiterates
$25
2024-11-11
Reason
HC Wainwright & Co.
Amit Dayal
Price Target
$25
2024-11-11
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cibus Inc (CBUS.O) is -1.15, compared to its 5-year average forward P/E of -3.17. For a more detailed relative valuation and DCF analysis to assess Cibus Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.17
Current PE
-1.15
Overvalued PE
-0.78
Undervalued PE
-5.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.94
Undervalued EV/EBITDA
-6.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
56.83
Current PS
1.25
Overvalued PS
140.52
Undervalued PS
-26.85
Financials
Annual
Quarterly
FY2025Q2
YoY :
+11.34%
933.00K
Total Revenue
FY2025Q2
YoY :
-16.46%
-17.95M
Operating Profit
FY2025Q2
YoY :
-6.74%
-26.56M
Net Income after Tax
FY2025Q2
YoY :
-46.49%
-0.61
EPS - Diluted
FY2025Q2
YoY :
-20.44%
-13.70M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
-50.83%
-1.11K
FCF Margin - %
FY2025Q2
YoY :
-16.24%
-2.85K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
171.3K
USD
48
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
171.3K
USD
48
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CBUS News & Events
Events Timeline
2025-10-16 (ET)
2025-10-16
07:50:37
Cibus and AgVaya Partner to Develop Solutions for Rice Farmers in India
2025-10-02 (ET)
2025-10-02
07:01:51
Cibus Finishes Field Trials for Second-Generation Herbicide-Tolerant Canola
2025-08-28 (ET)
2025-08-28
07:09:43
Cibus Forms Partnership with Latin American Rice Hybrid Consortium
Sign Up For More Events
Sign Up For More Events
News
4.5
11-07TipRanksVTI ETF Daily Briefing: Key Information for Investors – November 7, 2025
4.5
11-06TipRanksVTI ETF Daily Briefing: Key Information for Investors – November 6, 2025
4.5
11-05TipRanksVTI ETF Daily Briefing: Key Information for Investors – November 5, 2025
Sign Up For More News
People Also Watch
IOR
Income Opportunity Realty Investors Inc
17.800
USD
0.00%
TISI
Team Inc
15.840
USD
-0.13%
FDSB
Fifth District Bancorp Inc
13.170
USD
-0.23%
ISRL
Israel Acquisitions Corp
12.400
USD
-0.72%
XTNT
Xtant Medical Holdings Inc
0.753
USD
-4.68%
FSI
Flexible Solutions International Inc (Pre-Reincorporation)
8.300
USD
-0.60%
WOK
Work Medical Technology Group Ltd
3.660
USD
+0.83%
QNCX
Quince Therapeutics Inc
1.560
USD
-1.89%
FAQ
What is Cibus Inc (CBUS) stock price today?
The current price of CBUS is 1.31 USD — it has increased 4.38 % in the last trading day.
What is Cibus Inc (CBUS)'s business?
What is the price predicton of CBUS Stock?
What is Cibus Inc (CBUS)'s revenue for the last quarter?
What is Cibus Inc (CBUS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cibus Inc (CBUS)'s fundamentals?
How many employees does Cibus Inc (CBUS). have?